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Abstract To report a new screening method for mitochondrial DNA 1555A→G mutation and the results of
genotype analysis in 19 maternal inherited deafness pedigrees. Method Five hundred and forty-six non-syndromic
neuro-sensory hearing loss patients were tested for 1555A→G mutation using a new compact testing kit, which al-
lows clear distinction between wild type and 1555 A→G mutated mtDNAs. Results Nineteen subjects among the
546 patients (3.48%) were found to carry mtDNA A1555G mutation. The results were confirmed by sequencing in
an ABI 3100 Avant sequencer. Conclusions Maternal inherited deafness families are a frequently seen in outpa-
tient group. The detection of mtDNA 1555 A→G mutation with a low cost, ready to use detection kit is needed
and suitable in China for large scale screening and preventive testing before usage of aminoglycoside antibiotics.
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Mitochondrial DNA(mtDNA) mutations have
been found to be associated with sensorineural hearing
loss.(Fishel-Ghodsian 1999, and Joacobs 2003) In par-
ticular, the 12S rRNA gene has been shown to be a hot
spot for aminoglycoside induced and non-syndromic
hearing loss in different populations across the world.
Several deafness associated mtDNA mutations have
been identified in this gene. Obviously, the A1555G
mutation in the highly conserved decoding site of the
12S rRNA has been associated with both aminoglyco-
side-induced and non-syndromic hearing loss in many
families of different ethnic backgrounds.(Prezant et al,
1993; Estivill et al, 1998; Li et al, 2004) In China,
there have been numerous reports on the pathogenesis
of maternal inherited deaf families closely related to
both A1555G mutation and administration of aminogly-
coside antibiotics. But most of these studies have fo-
cused on families with unique maternal inherited pat-
terns and ignored families with only one or two deaf
patients. A systematic and extended mtDNA A1555G
mutation screening project using a compact testing kit
has been initiated for the patient population at the Otolo⁃
gy Clinic of the Chinese PLA General Hospital, Beijing,
China. As a consequence of this study, 19 deaf pro-
bands have been identified as carrying A1555G muta-
tion. Reported in this paper is a comprehensive investi-
gation of the pedigrees including family size, number
of deaf patients and asymptomatic carriers and a discus-
sion on significance of A1555G screening in prevent-
ing aminoglycoside related hearing loss.
Subjects and methods
Subjects, clinical and family data
All 546 screened candidates were non-syndromic
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neuro-sensory hearing loss patients, and were ascer-
tained at the Otology Clinic at PLA General Hospital.
Consent documents for all participants were signed by
patients or guardians. Comprehensive history intake
and physical examination were performed to identify
any syndromic findings, history of use of aminoglyco-
sides, or other genetic factors associated with hearing
impairment. An age-appropriate audiological evalua-
tion was performed, including pure-tone audiometry
(PTA), immittance testing and/or auditory brainstem re-
sponse(ABR). An average hearing threshold, calculat-
ed from the thresholds at 500, 1000 and 2000 and 4000
Hz, was used to classify the severity of hearing impair-
ment into four grades: normal＜26 dB HL; mild = 26－
40 dB HL; moderate = 41－70 dB HL; severe = 71－
90 dB HL; and profound＞90 dB HL.
Mitochondrial DNA A1555G screening
Genomic and mitochondrial DNA was isolated
from whole blood of participants using the Watson
DNA Isolation Kits(Shanghai, China) stored at -70℃ .
The PCR amplification, mutation analysis and identifi-
cation procedures all followed the user manual of mtD-
NA A1555G Mutation Testing Kit(Manufacturer: Wei-
hai Aomaier Gene Technological CO., LTD.,Weihai,
Shandong) (Fig.1). Absence of mtDNA A1555G muta-
tion was determined by the sole presence of 111bp
band on the final checking electrophoresis, while the
presence of 91bp and 20bp bands (absent or faint on the
agarose gel in normal subjects) was considered to repre-
sent the existence of mtDNA A1555G mutation (Fig.
２).
All positive samples and some of randomly select-
ed negative samples were confirmed by PCR direct se-
quencing in an ABI 3100 Avant sequencer.
Results
Nineteen in the 546 screened patients were found
to carry mtDNA A1555G mutation. The mutation rate
in this patient population was 3.48% . Of the 19 pro-
bands carrying mtDNA A1555G mutation, 13 were
males and 6 were females. Their ages ranged from 7 to
33 years(average 16.53 ± 5.32 years). Of the pedigrees
of the 19 probands, two lost contact after the first visit
and 1 declined to provide family information in detail.
The rest 16 pedigrees provided comprehensive family
information including family size, pedigree trees, num-
ber of patients with hearing impairment in the family
and medical histories. Of the 16 probands whose pedi-
gree information was collected, 12 were males and 4
were females, with an average age of 17.44 ± 5.48
years. The onset age of hearing loss ranged from 0.67
to 33 years(average 4.1 ± 7.81 years). All 16 probands
had history of medicine administration before hearing
loss. In 15 cases, there was a clear history of aminogly-
coside administration before hearing loss. The detailed
pedigree schemes were made for all families of these
16 probands. There were a total of 267 living matrilin-
eal family members(117 males and 150 females) in-
cluding the probands. Thirty two of these matrilineal
members( 17 males and 15 females) suffered hearing
loss and the rest 235 members (100 males and 135 fe-
males) had normal hearing. Indeed, the sequence analy-
sis confirmed the presence of A1555G mutation in all
subjects who were tested positive for A1555G muta-
tion by the compact testing kit.
Discussion
Mitochondrial DNA is the only genome existing
in cytoplasm which has functions of self-replication,
transcription and coding modified by nuclear genome.
In the process of sexual reproduction, almost all mito-
chondrial DNA in the offspring is transmitted from the
cytoplasm of the ovum. This feature is the genetic ba-
sis of maternal inheritence patterns. Since 1993, there
have been numerous reports and studies showing that
A1555G mutation is one of the most common muta-
Ｆig.2 Qualification of the A1555G mutation in 21 Chinese
subjects with aminoglycoside-induced and non-syndromic
hearing loss. PCR products around the A1555G region of mi-
tochondrial genome have been digested using the testing kit
and analyzed using electrophoresis in a 2.5% agarose gel
stained with ethidrum bromide. Plus denotes the positive
control and minus denotes the negative control.
Fig.1 Polymerase chain reaction for detection of mtDNA
A1555G mutation. Lanes 1 to 20 are PCR products of Chinese
subjects with aminoglycoside-induced and non-syndromic
hearing loss. Plus denotes the positive control and minus
denotes the negative control.
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tions in mitochondrial genome which can cause
non-syndromic hearing loss, often precipitated by use
of aminoglycoside. However, there has been no direct
evidence to support that mtDNA 1555 site is a hot spot
for de Novo mutation. It can therefore be predicted that
for a female ancestor carrying A1555G mutation, the
number of her matrilineal offspring with the same mu-
tation will keep increasing as generations expand.
Aminoglycoside antibiotics (streptomycin, genta-
mycin, neomycin, kanamycin, tobramycin, micronomi-
cin and ribostamycin) were widely used, and in many
cases over-used, nationwide in China from the 1960s
to 1980s, as they were considered cost-effective in con-
trolling infections by a wide spectrum of bacteria.
Even with large number of reports on aminoglycoside
induced hearing loss in China and in other countries,
aminoglycoside and a few new synthetic deritives from
traditional aminoglycosides, such as amikacin, netilmi-
cin, etimicin, isepamicin, are still being used in clinics
all over China, especially in low income areas includ-
ing mountainous and underdeveloped areas. These
drugs are known to exert their antibacterial effects by
directly binding to 16S ribosomal RNA (rRNA) in the
30S subunit of the bacterial ribosome, causing mis-
translation or premature termination of protein synthe-
sis.(Chamber and Sande, 1996; Davis and Davis, 1968)
Mitochondrial ribosomes share more similarities to bac-
terial ribosomes than do cytosolic ribosomes.(Fisch-
el-Ghodsian, 2005; Guan, 2005). Therefore, it is pro-
posed that the ototoxic site of aminoglycosides is the
mitochondrial ribosome. Patients with hearing loss in-
duced by aminoglycoside can be divided into two
types - those who have received over-dose(ototoxic
dose) of aminoglycosides without evidence of precipi-
tating genetic background and those who are treated
with normal dose, sometimes one single dose, of ami-
noglycoside but with maternal inheritance background.
In particular, susceptibility to aminoglycoside-induced
hearing loss is maternally inherited in humans in a sig-
nificant proportion of cases, particularly in the Chinese
population.(Hu et al, 1991, Higashi, 1989; Li et al,
2005) In fact, the new U－A or G-C pair in 12S rRNA
created by the A1555G or C1494T transition facilitates
the binding of aminoglycosides.(Prezant et al, 2003;
Hamasaki and Rando, 1997) The previous biochemical
data provided by Guan indicate that the A1555G or
C1494T mutation leads to the sensitivity to aminogly-
cosides.(Zhao et al, 2004; Zhao et al, 2005; Guan et al,
1996; Guan et al, 2000)
In 1993, Hutchin(Hutchin et al, 1993) investigated
sequence variation of 12S and 16S rRNA genes in three
Chinese pedigrees with AGD(aminoglycoside-induced
deafness) carried on the mitochondrial DNA, and all
three pedigrees were confirmed to carry mtDNA
A1555G mutation. The 1555 A to G mutation results in
the loss of the BsmAI restriction site in the PCR prod-
uct. In control, the mtDNA A1555G mutation never oc-
curred in 414 hearing people and 34 aminoglycoside-re-
sistant individuals. Since then, direct sequencing or en-
zyme digestion by BsmAI has become standard proto-
cols to detect the existence of mtDNA A1555G muta-
tion. In 1996, Inoue(Inoue et al, 1996) further con-
firmed that the homoplasmic 1555 mtDNA mutation is
involved in the pathogenesis leading to aminoglyco-
side-induced hearing loss. But further studies by Guan
and other authors showed that the A1555G mutation it-
self is not sufficient to produce the clinical pheno-
type(Prezant et al, 1993; Li et al, 2004; Guan et al,
1996; Young et al, 2005; Guan et al, 2001) and amino-
glycosides are the major modifier factor for the devel-
opment of deafness. Although there are a few of reports
on applying chemical protector or antioxidant thera-
py(Schacht 1999; Wang et al, 2001; Dai et al, 2005) to
reduce hearing loss induced by ototoxic drugs, univer-
sal clinic data have not shown any progress in treating
such ototoxic hearing loss. Thus, prevention through de-
tection of mtDNA A1555G mutation and avoiding ex-
posing mutation carriers to aminoglycoside agents play
a critical role in preventing aminoglycoside-induced
deafness in practice. In this study, identifying one
A1555G mutation carrier may provide alert and guide
future antibiotic therapy for an average 15 matrilineal
relatives.
In this study, a compact testing kit method was
used to detect mtDNA A1555G mutation in a large out-
patient deaf patient group. The reason for employing
this compact testing kit method is that BsmAI is not
manufactured in China and significantly more expen-
sive than the compact testing kit. When cost and ship-
ping time are taken into consideration, the compact test-
ing kit method stands out as effective and financially
feasible in such mutation screening in China. The fidel-
ity of this assay was proved to be 100% accurate
through over 50 sequencings of 12S rRNA in all posi-
tive and randomly selected negative cases in this study.
Among the 16 families carrying mtDNA A1555G
mutation in this study, 11 had only 1 or 2 matrilineal
family members showing hearing loss, most often in-
duced by using aminoglycoside antibiotics. General
speaking, discovering one A1555G carrier will alert
more than 15 matrilineal relatives and guide prescrip-
tion for these individuals. It is difficult to recognize
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these sporadic or sporadic-like cases with A1555G mu-
tation solely based upon family history and medical re-
cords review. Molecular diagnosis is the only way to
elucidate the real etiology for these sporadic cases. A to-
tal of 235 unaffected A1555G carriers were identified
through comprehensive family history and pedigree
analysis. These families were informed of their condi-
tion as A1555G mutation carriers, their susceptibility to
aminoglycoside-induced deafness, list of these medi-
cine and risks of aminoglycoside administration. These
A1555G carriers will benefit from the molecular screen-
ing and are expected to face reduced risks of hearing
damage induced by aminoglycoside. It can be predicted
that the incidence of ototoxic hearing loss induced by
aminoglycoside in China will be decreased dramatical-
ly through implementing universal genetic screening in
pregnant women and / or new born babies in the future.
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